Imvax

Imvax

Biotechnology, 601 Walnut St, Philadelphia, Pennsylvania, 19106, United States, 11-50 Employees

imvax.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 26********

Who is IMVAX

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvaxs combination therapy uniquely captures the complete antigenic signature...

Read More

map
  • 601 Walnut St, Philadelphia, Pennsylvania, 19106, United States Headquarters: 601 Walnut St, Philadelphia, Pennsylvania, 19106, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from IMVAX

Imvax Org Chart and Mapping

Employees

Raechel Manrodt

Manufacturing Lead (Director)

Samantha Boich

Quality Control Associate

Michelle Christman

Quality Assurance Document Control (Qadc)

Kelsey Herbst

Analytical Quality Control Associate II

Gregory Grevera

Field Based Medical Affairs - Imvax

Anthony Zuccarello

Head of Supply Chain, Logistics, Procurement & Planning

Humeyra Kahraman

Qc Associate Microbiology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Imvax

Answer: Imvax's headquarters are located at 601 Walnut St, Philadelphia, Pennsylvania, 19106, United States

Answer: Imvax's phone number is 26********

Answer: Imvax's official website is https://imvax.com

Answer: Imvax's revenue is $25 Million to $50 Million

Answer: Imvax's SIC: 2834

Answer: Imvax has 11-50 employees

Answer: Imvax is in Biotechnology

Answer: Imvax contact info: Phone number: 26******** Website: https://imvax.com

Answer: Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvaxs combination therapy uniquely captures the complete antigenic signature of a patients own tumor and converts it into a highly stimulatory training program for the patients immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects. The companys lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access